TargetBeta
SIRPA
signal regulatory protein alpha · also SHPS1, SIRP, MYD-1, BIT · CD molecules
3 programs in company-led studies act on SIRPA, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-SIRPa Monoclonal Antibody BI 770371rule | Boehringer Ingelheim | – | phase 2 | 43 running | – | NCIt |
| Anti-SIRPa Monoclonal Antibody DS-1103rule | Daiichi Sankyo | – | phase 2 | 22 running | – | NCIt |
| Anti-SIRPalpha Monoclonal Antibody BYON4228rule | Byondis | – | phase 1 | 22 running | – | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Fatty Liver, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Squamous Cell Carcinoma of Head and Neck, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 31, 2027Anti-SIRPa Monoclonal Antibody BI 770371 · Boehringer Ingelheim · phase 2 · NCT06806852
- May 31, 2029Anti-SIRPa Monoclonal Antibody DS-1103 · Daiichi Sankyo · phase 2 · NCT05765851
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.